−3.3150USD
−9.64 MUSD
14.73 MUSD
35.87 M
About NovaBay Pharmaceuticals, Inc.
Sector
CEO
Justin M. Hall
Headquarters
Emeryville
Website
Employees (FY)
26
Founded
2000
ISIN
US66987P3001
FIGI
BBG000PVPJT3
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NBY is 0.0840 USD — it has increased by 1.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange NovaBay Pharmaceuticals, Inc. stocks are traded under the ticker NBY.
NovaBay Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
NBY stock is 12.59% volatile and has beta coefficient of 0.71. Check out the list of the most volatile stocks — is NovaBay Pharmaceuticals, Inc. there?
One year price forecast for NovaBay Pharmaceuticals, Inc. has a max estimate of 3.2000 USD and a min estimate of 2.0000 USD.
NBY earnings for the last quarter are −0.37 USD whereas the estimation was −0.41 USD which accounts for 8.64% surprise. Estimated earnings for the next quarter are −0.30 USD. See more details about NovaBay Pharmaceuticals, Inc. earnings.
NovaBay Pharmaceuticals, Inc. revenue for the last quarter amounts to 3.27 M USD despite the estimated figure of 3.55 M USD. In the next quarter revenue is expected to reach 3.40 M USD.
Yes, you can track NovaBay Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NBY stock has fallen by 10.64% compared to the previous week, the month change is a 41.18% fall, over the last year NovaBay Pharmaceuticals, Inc. has showed a 95.09% decrease.
NBY net income for the last quarter is −4.11 M USD, while the quarter before that showed −1.76 M USD of net income which accounts for −133.81% change. Track more NovaBay Pharmaceuticals, Inc. financial stats to get the full picture.
Today NovaBay Pharmaceuticals, Inc. has the market capitalization of 2.99 M, it has decreased by 11.61% over the last week.
No, NBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovaBay Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 26.00 employees. See our rating of the largest employees — is NovaBay Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NovaBay Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NovaBay Pharmaceuticals, Inc. stock shows the sell signal. See more of NovaBay Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NovaBay Pharmaceuticals, Inc. future price: according to them, NBY price has a max estimate of 3.20 USD and a min estimate of 2.00 USD. Read a more detailed NovaBay Pharmaceuticals, Inc. forecast: see what analysts think of NovaBay Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovaBay Pharmaceuticals, Inc. EBITDA is −4.80 M USD, and current EBITDA margin is −32.60%. See more stats in NovaBay Pharmaceuticals, Inc. financial statements.